Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Modeling Progression of CML Using Mutagenized Patient-Derived Induced Pluripotent Stem Cells (iPSCs): Potential Tool for Discovering Novel Therapeutic Targets

Jusuf Imeri, Christophe Desterke, Gladys Telliam, Paul Marcoux, Nathalie Sorel, Safa Sanekli, Sylvain Barreau, Yücel Erbilgin, Theodoros Latsis, Patricia Hugues, Emilie Cayssials, Jean Claude Chomel, Annelise Bennaceur Griscelli, Ali G Turhan

Blood (2022) 140 (Supplement 1): 12173–12174.

https://doi.org/10.1182/blood-2022-156075

Published: 2022

Journal Articles

Revisiting Early Stages of Chronic Myeloid Leukemia (CML): Evidence That Leukemic Progenitors Appear First in Peripheral Blood during Molecular Recurrence

Ali G Turhan, MD PhD, Patricia Hugues, Nathalie Sorel, Christophe Desterke, Annelise Bennaceur-Griscelli, MD PhD, Jean-Claude Chomel, PharmD PhD

Blood (2018) 132 (Supplement 1): 5425.

https://doi.org/10.1182/blood-2018-99-110676

Published: 2018

Journal Articles

ETS1 Expression Is Upregulated in Chronic Myeloid Leukemia (CML) and the ETS1 Transcriptional Program Correlates with Disease Progression Towards Blast Crisis

Christophe Desterke, PhD, Maud Voldoire, MD, Nathalie Sorel, Marie Laure Bonnet, Sarah Pagliaro, PharmD, Annelise Bennaceur-Griscelli, MD PhD, Emilie Cayssials, MD, Jean-Claude Chomel, PharmD PhD, Ali G Turhan, MD, PhD

Blood (2016) 128 (22): 442.

https://doi.org/10.1182/blood.V128.22.442.442

Published: 2016

Journal Articles

The Cell Surface NADH Oxidase ENOX2 Is Highly Expressed in Chronic Myeloid Leukemia (CML): a Redox Protein As a Secreted Surrogate Biomarker and Druggable Target

Seda Baykal, Maud Voldoire, MD, Christophe Desterke, Nathalie Sorel, Hyacinthe Atchroue Johnson Ansah, Agnes Guerci-Bresler, MD, Jean-Claude Chomel, PharmD PhD, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD, PhD

Blood (2016) 128 (22): 3059.

https://doi.org/10.1182/blood.V128.22.3059.3059

Published: 2016

Journal Articles

Superoxide Dismutase 2 (Sod2) Expression Is Highly Decreased In Chronic Myeloid Leukemia (CML): Contribution To Genetic Instability In Bcr-Abl-Expressing Leukemic Cells

Sandrine Girerd, Lucie Tosca, PharmD, PhD, Olivier Herault, MD, PhD, Christine Vignon, PhD, Denis Biard, PhD, Fatima Dkhissi, PhD, Clémentine Bouneau, Djamel Aggoune, Angelina Bertrand, Marie Laure Bonnet, Nathalie Sorel, PhD, Gerard Tachdjian, MD, PhD, François Guilhot, MD, Joelle Guilhot, PhD, Jean-Claude Chomel, PharmD, PhD, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 3980.

https://doi.org/10.1182/blood.V122.21.3980.3980

Published: 2013

Journal Articles

BRCA1-Down-Regulation In Chronic Myeloid Leukemia (CML) Occurs Via The Deubiquitinase / Tumor Suppressor BRCA1-Associated Protein 1 (BAP1)

Fatima Dkhissi, PhD, Djamel Aggoune, Julien Pontis, Marie Laure Bonnet, Marie Claude Meunier, Nathalie Sorel, PhD, Clémentine Bouneau, Annelise Bennaceur-Griscelli, MD, PhD, François Guilhot, MD, Jean-Claude Chomel, PharmD, PhD, Slimane Ait-Si-Ali, PhD, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 3813.

https://doi.org/10.1182/blood.V122.21.3813.3813

Published: 2013

Journal Articles

A Niche-Based Cell Mutagenesis Assay Identifies ABL-Kinase Mutations Appearing in BCR-ABL T315I-Mutated Leukemic Cells Treated with Ponatinib.

Djamel Aggoune, Nathalie Sorel, PhD, Marie Laure Bonnet, Jean-Claude Chomel, PharmD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 2436.

https://doi.org/10.1182/blood.V120.21.2436.2436

Published: 2012

Journal Articles

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Jean-Claude Chomel, PharmD, PhD, Marie Laure Bonnet, Nathalie Sorel, PhD, Ivan Sloma, PharmD, PhD, Alexis Proust, Annelise Bennaceur-Griscelli, MD, PhD, Delphine Rea, MD, PhD, Madalina Uzunov, M.D., Laurence Legros, MD, PhD, Shanti Ame, MD, Anne Marfaing-Koka, Agnès Guerci, MD, Philippe Rousselot, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 3726.

https://doi.org/10.1182/blood.V120.21.3726.3726

Published: 2012

Journal Articles

Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk

Djamel Aggoune, Nathalie Sorel, PhD, Sanaa El Marsafy, MD, PhD, Marie Laure Bonnet, Denis Clay, Marie Claude Meunier, Karin Tarte, Olivier Herault, MD, PhD, Jorge Domenech, MD, PhD, Agnès Guerci, MD, Jean-Claude Chomel, PharmD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 908.

https://doi.org/10.1182/blood.V120.21.908.908

Published: 2012

Journal Articles

BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia

Jean-Claude Chomel, Nathalie Sorel, Joëlle Guilhot, François Guilhot, Ali G. Turhan

Blood (2012) 119 (12): 2964–2965.

https://doi.org/10.1182/blood-2011-12-396226

Published: 2012

Journal Articles

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

Jean-Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, Angelina Bertrand, Marie-Claude Meunier, Serge Fichelson, Michael Melkus, Annelise Bennaceur-Griscelli, François Guilhot, Ali G. Turhan

Blood (2011) 118 (13): 3657–3660.

https://doi.org/10.1182/blood-2011-02-335497

Published: 2011

Includes: Supplemental data

Journal Articles

T315I Mutation INCREASES the GENOMIC Instability and the Mutator Phenotype IN BCR-ABL-Expressing LEUKEMIC CELLS.

Djamel Aggoune, Angelina Bertrand, Marie Laure Bonnet, Amelie Le Corf, Sandrine Girerd, Fatima Dkhissi, PhD, Nathalie Sorel, PhD, Jean-Claude Chomel, PharmD, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Ali G. Turhan, MD, PhD

Blood (2010) 116 (21): 3365.

https://doi.org/10.1182/blood.V116.21.3365.3365

Published: 2010

Journal Articles

Persistence of BCR-ABL-Expressing LEUKEMIC STEM CELLS IN Chronic MYELOID LEUKEMIA (CML) PATIENTS IN COMPLETE REMISSION with Undetectable MOLECULAR Disease

Jean-Claude Chomel, Marie Laure Bonnet, Nathalie Sorel, Angelina Bertrand, Marie Claude Meunier, Michael Melkus, Annelise Bennaceur-Griscelli, MD, PhD, Francois Guilhot, Ali G. Turhan, MD, PhD

Blood (2010) 116 (21): 883.

https://doi.org/10.1182/blood.V116.21.883.883

Published: 2010

Journal Articles

Comparative Effects of Wild Type and T315I Mutated bcr-ABL in Murine Embryonic Stem-Cell Derived Hematopoiesis.

Michael Melkus, PhD, Maria Theresa Mitjavila-Garcia, PhD, Marie-Laure Bonnet, Nathalie Sorel, Jean-Claude Chomel, Annelise Bennaceur-Griscelli, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2008) 112 (11): 1075.

https://doi.org/10.1182/blood.V112.11.1075.1075

Published: 2008

Journal Articles

Quantitative Monitoring of BCR-ABL mRNA Harboring the T315I Mutation in Chronic Myeloid Leukemia (CML).

Jean-Claude Chomel, PharmD, PhD, Nathalie Sorel, PhD, Francois Guilhot, MD, Ali G. Turhan, MD, PhD

Blood (2007) 110 (11): 2919.

https://doi.org/10.1182/blood.V110.11.2919.2919

Published: 2007

Journal Articles

N-GAL Expression Correlates with Disease Status in Chronic Myelogenous Leukemia (CML).

Claire Villalva, PhD, Nathalie Sorel, PhD, Marie-Laure Bonnet, Francois Guilhot, MD, Jean-Claude Chomel, PhD, Ali G. Turhan, MD, PhD

Blood (2006) 108 (11): 4782.

https://doi.org/10.1182/blood.V108.11.4782.4782

Published: 2006

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

Sequential emergence of ABL -kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

Nathalie Sorel, Lydia Roy, Géraldine Martineau, François Guilhot, Ali G. Turhan, Jean-Claude Chomel

Blood (2006) 108 (5): 1782–1783.

https://doi.org/10.1182/blood-2006-03-011668

Published: 2006

Includes: Supplemental data

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

NARROW

Modeling Progression of CML Using Mutagenized Patient-Derived Induced Pluripotent Stem Cells (iPSCs): Potential Tool for Discovering Novel Therapeutic Targets

Revisiting Early Stages of Chronic Myeloid Leukemia (CML): Evidence That Leukemic Progenitors Appear First in Peripheral Blood during Molecular Recurrence

ETS1 Expression Is Upregulated in Chronic Myeloid Leukemia (CML) and the ETS1 Transcriptional Program Correlates with Disease Progression Towards Blast Crisis

The Cell Surface NADH Oxidase ENOX2 Is Highly Expressed in Chronic Myeloid Leukemia (CML): a Redox Protein As a Secreted Surrogate Biomarker and Druggable Target

Superoxide Dismutase 2 (Sod2) Expression Is Highly Decreased In Chronic Myeloid Leukemia (CML): Contribution To Genetic Instability In Bcr-Abl-Expressing Leukemic Cells

BRCA1-Down-Regulation In Chronic Myeloid Leukemia (CML) Occurs Via The Deubiquitinase / Tumor Suppressor BRCA1-Associated Protein 1 (BAP1)

A Niche-Based Cell Mutagenesis Assay Identifies ABL-Kinase Mutations Appearing in BCR-ABL T315I-Mutated Leukemic Cells Treated with Ponatinib.

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk

BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

T315I Mutation INCREASES the GENOMIC Instability and the Mutator Phenotype IN BCR-ABL-Expressing LEUKEMIC CELLS.

Persistence of BCR-ABL-Expressing LEUKEMIC STEM CELLS IN Chronic MYELOID LEUKEMIA (CML) PATIENTS IN COMPLETE REMISSION with Undetectable MOLECULAR Disease

Comparative Effects of Wild Type and T315I Mutated bcr-ABL in Murine Embryonic Stem-Cell Derived Hematopoiesis.

Quantitative Monitoring of BCR-ABL mRNA Harboring the T315I Mutation in Chronic Myeloid Leukemia (CML).

N-GAL Expression Correlates with Disease Status in Chronic Myelogenous Leukemia (CML).

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Sequential emergence of ABL -kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only